Target type: biologicalprocess
Any process that stops, prevents, or reduces the frequency, rate or extent of macrophage apoptotic process. [GOC:BHF, GOC:mtg_apoptosis]
Negative regulation of macrophage apoptotic process is a complex biological process that involves a coordinated interplay of signaling pathways, transcription factors, and effector molecules. Macrophages are phagocytic cells of the immune system that play a crucial role in tissue homeostasis and host defense against pathogens. However, excessive macrophage apoptosis can contribute to inflammation and tissue damage. Therefore, tight regulation of macrophage apoptosis is essential for maintaining immune system integrity.
The process of negative regulation of macrophage apoptosis can be initiated by various stimuli, including growth factors, cytokines, and microbial products. These stimuli activate signaling pathways that promote cell survival and inhibit apoptosis.
**Key Signaling Pathways Involved in Negative Regulation of Macrophage Apoptosis:**
* **PI3K/Akt Pathway:** Activation of the PI3K/Akt pathway is a major survival signal in macrophages. PI3K is a lipid kinase that is activated by various stimuli, including growth factors and cytokines. Activated PI3K phosphorylates phosphatidylinositol (4,5)-bisphosphate (PIP2) to produce phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 acts as a docking site for Akt, a serine/threonine kinase. Akt phosphorylation by PI3K activates Akt, which in turn phosphorylates and inhibits pro-apoptotic proteins, such as Bad and caspase-9.
* **NF-κB Pathway:** NF-κB is a transcription factor that plays a crucial role in regulating inflammatory and immune responses. Activation of NF-κB by various stimuli, including TNF-α and LPS, promotes the expression of anti-apoptotic genes, such as Bcl-2 and Bcl-xL. These proteins inhibit the release of cytochrome c from mitochondria, a critical step in the apoptotic cascade.
* **MAPK Pathway:** Mitogen-activated protein kinases (MAPKs) are a family of serine/threonine kinases that are involved in various cellular processes, including apoptosis. Activation of MAPKs, such as ERK, JNK, and p38, can either promote or inhibit apoptosis depending on the specific MAPK pathway involved and the cellular context. In general, activation of ERK promotes survival, while activation of JNK and p38 promotes apoptosis.
* **JAK/STAT Pathway:** The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway is a major signaling pathway activated by cytokines. Upon cytokine binding to its receptor, JAKs are activated and phosphorylate STAT proteins. Activated STATs dimerize and translocate to the nucleus, where they regulate gene expression, including the expression of anti-apoptotic genes.
**Effector Molecules Involved in Negative Regulation of Macrophage Apoptosis:**
* **Anti-apoptotic proteins:** Bcl-2 family proteins, such as Bcl-2, Bcl-xL, and Mcl-1, are key inhibitors of apoptosis. These proteins localize to mitochondria and prevent the release of cytochrome c, a crucial step in the apoptotic cascade.
* **Inhibitors of caspases:** Caspases are cysteine proteases that play a central role in apoptosis. Caspase inhibitors, such as XIAP and cIAP1/2, bind to and inhibit caspases, thereby preventing the execution of apoptosis.
* **Apoptosis-inducing factor (AIF):** AIF is a mitochondrial protein that can induce caspase-independent apoptosis. However, certain stimuli, such as growth factors and cytokines, can inhibit AIF translocation to the nucleus, thereby preventing apoptosis.
**Regulation of Negative Regulation of Macrophage Apoptosis:**
The process of negative regulation of macrophage apoptosis is tightly regulated to ensure that macrophages survive when needed and undergo apoptosis when appropriate. This regulation is achieved through various mechanisms, including:
* **Crosstalk between signaling pathways:** The various signaling pathways involved in negative regulation of macrophage apoptosis are interconnected and can influence each other's activity. For example, activation of the PI3K/Akt pathway can inhibit the activation of the JNK pathway.
* **Post-translational modifications:** The activity of various proteins involved in negative regulation of macrophage apoptosis can be modulated by post-translational modifications, such as phosphorylation, acetylation, and ubiquitination.
* **Microenvironment:** The surrounding microenvironment can significantly influence the apoptotic fate of macrophages. For example, the presence of pathogens or inflammatory cytokines can promote apoptosis, while the presence of growth factors or cytokines can promote survival.
**Disruption of Negative Regulation of Macrophage Apoptosis in Disease:**
Disruption of the negative regulation of macrophage apoptosis can contribute to various diseases. For example, excessive macrophage apoptosis can contribute to inflammation and tissue damage in diseases such as rheumatoid arthritis, Crohn's disease, and Alzheimer's disease. Conversely, defective macrophage apoptosis can promote tumor growth and metastasis.
**Conclusion:**
Negative regulation of macrophage apoptotic process is a complex and tightly regulated process that is essential for maintaining immune system integrity. This process involves a coordinated interplay of signaling pathways, transcription factors, and effector molecules. Disruption of this process can contribute to various diseases. Therefore, understanding the mechanisms involved in negative regulation of macrophage apoptosis is crucial for developing novel therapeutic strategies for the treatment of these diseases.'
"
Protein | Definition | Taxonomy |
---|---|---|
Nucleotide-binding oligomerization domain-containing protein 2 | A nucleotide-binding oligomerization domain-containing protein 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9HC29] | Homo sapiens (human) |
Growth hormone secretagogue receptor type 1 | A growth hormone secretagogue receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q92847] | Homo sapiens (human) |
C-C chemokine receptor type 5 | A C-C chemokine receptor type 5 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P51681] | Homo sapiens (human) |
Beta-galactoside alpha-2,6-sialyltransferase 1 | A beta-galactoside alpha-2,6-sialyltransferase 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P15907] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
1,10-phenanthroline | 1,10-phenanthroline: RN given refers to parent cpd; inhibits Zn-dependent metalloproteinases | phenanthroline | EC 2.7.1.1 (hexokinase) inhibitor; EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor |
2,2'-dipyridyl | 2,2'-bipyridine : A bipyridine in which the two pyridine moieties are linked by a bond between positions C-2 and C-2'. 2,2'-Dipyridyl: A reagent used for the determination of iron. | bipyridine | chelator; ferroptosis inhibitor |
disulfiram | organic disulfide; organosulfur acaricide | angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor | |
terfenadine | Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME. | diarylmethane | |
4,4'-dimethyl-2,2'-bipyridine | 4,4'-dimethyl-2,2'-bipyridine: structure in first source | ||
5,5'-dimethyl-2,2'-bipyridyl | 5,5'-dimethyl-2,2'-bipyridyl: structure in first source | bipyridines | |
paclitaxel | Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL). | taxane diterpenoid; tetracyclic diterpenoid | antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent |
substance p | peptide | neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent | |
neocuproine | neocuproine : A member of the class of phenanthrolines that is 1,10-phenanthroline bearing two methyl substituents at positions 2 and 9. neocuproine: Spectrophotometric determination of copper and ultramicro blood sugar determinations; structure; RN given refers to parent cpd | phenanthrolines | chelator; copper chelator |
2,2',2''-terpyridine | 2,2',2''-terpyridine: RN given refers to parent cpd 2,2':6',2''-terpyridine : A tridentate heterocyclic ligand that binds metals at three meridional sites giving two adjacent 5-membered MN2C2 chelate rings. | terpyridines | chelator |
5-methyl-1,10-phenanthroline | |||
3,4,7,8-tetramethyl-1,10-phenanthroline | |||
l 692429 | L 692429: stimulates release of growth hormone; RN refers to (R)-isomer; structure given in first source | ||
docetaxel anhydrous | docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group. Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER. | secondary alpha-hydroxy ketone; tetracyclic diterpenoid | antimalarial; antineoplastic agent; photosensitizing agent |
l 163191 | |||
tak 779 | |||
cp 424391 | CP 424391: a growth hormone secretagogue; structure in first source | ||
cytidine monophosphate n-acetylneuraminic acid | CMP-N-acetyl-beta-neuraminic acid : A nucleotide sugar used as a donor by glycosyltransferases for the synthesis of sugar chains Cytidine Monophosphate N-Acetylneuraminic Acid: A nucleoside monophosphate sugar which donates N-acetylneuraminic acid to the terminal sugar of a ganglioside or glycoprotein. | CMP-N-acyl-beta-neuraminic acid | mouse metabolite |
muramyl dipeptide | glycopeptide | immunological adjuvant | |
3-methyl-7-pentyl-8-(2-phenylethylthio)purine-2,6-dione | oxopurine | ||
3-methyl-7-(phenylmethyl)-8-(propan-2-ylthio)purine-2,6-dione | oxopurine | ||
1-(4-methylphenyl)sulfonyl-2-benzimidazolamine | sulfonamide | ||
1-(4-chlorophenyl)sulfonyl-2-benzimidazolamine | sulfonamide | ||
aplaviroc | aplaviroc: a spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1; structure in first source | ||
maraviroc | tropane alkaloid | ||
vicriviroc | vicriviroc: structure in first source | (trifluoromethyl)benzenes | |
1-(benzenesulfonyl)-2-benzimidazolamine | sulfonamide | ||
1-(4-nitrophenyl)sulfonyl-2-benzimidazolamine | sulfonamide | ||
tak-220 | TAK-220: structure in first source | ||
cp 481715 | quinoxaline-2-carboxylic acid (4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyloctyl)amide: a CCR1 antagonist and NSAID; structure in first source | ||
pd 166285 | |||
ancriviroc | Ancriviroc: CCR5 receptor antagonist | aromatic carboxylic acid; pyridinemonocarboxylic acid | |
variecolin | variecolin: structure in first source | enal; sesterterpenoid | Aspergillus metabolite |
hexarelin | hexarelin: a synthetic growth hormone releasing peptide; structurally similar to GHRP-6, with the substitution of D-Trp with its 2-methyl derivative; more potent & stable and less toxic than GHRP-6 | ||
ucb 35625 | UCB 35625: J-113863 is the (trans)-isomer; structure in first source | ||
sm 130686 | SM 130686: a growth hormone secretagogue; structure in first source | ||
macimorelin | |||
tabimorelin | tabimorelin: a growth hormone secretagogue; structure in first source | ||
l 162752 | |||
sk&f 110679 | |||
amd 070 | mavorixafor: a derivative of AMD3100; a CXCR4 blocker | aminoquinoline | |
cenicriviroc | cenicriviroc : A member of the class of benzazocines that is (5Z)-1,2,3,4-tetrahydro-1-benzazocine which is substituted by a 2-methylpropyl, N-{4-[(S)-(1-propyl-1H-imidazol-5-yl)methanesulfinyl]phenyl}carboxamide and 4-(2-butoxyethoxy)phenyl groups at positions 1, 5 and 8, respectively. It is a potent chemokine 2 and 5 receptor antagonist currently in development for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis (NASH). cenicriviroc: an inhibitor of HIV-1 | aromatic ether; benzazocine; diether; imidazoles; secondary carboxamide; sulfoxide | anti-HIV agent; anti-inflammatory agent; antirheumatic drug; chemokine receptor 2 antagonist; chemokine receptor 5 antagonist |
ulimorelin | ulimorelin: ghrelin agonist; an 18-membered macrocycle containing 3 amide bonds and a secondary amine as well as 4 stereogenic centers; belongs to macrocyclic peptidomimetics | oligopeptide | |
n-(3-fluorophenyl)-1-((4-(((3s)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine | N-(3-fluorophenyl)-1-((4-(((3S)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine: a small molecule motilin receptor agonist; structure in first source | acetamides | |
yil 781 | YIL 781: an appetite suppressant and weight loss promoter; structure in first source | ||
1-(4-methoxyphenyl)sulfonyl-2-benzimidazolamine | sulfonamide | ||
5,6-dimethyl-1-(4-methylphenyl)sulfonyl-2-benzimidazolamine | sulfonamide | ||
nitd 609 | NITD 609: an antimalarial and coccidiostat; structure in first source | ||
19,20-epoxycytochalasin q | 19,20-epoxycytochalasin Q: from Xylaria sp.; structure in first source | ||
gsk 2334470 | GSK 2334470: a PDK1 inhibitor; structure in first source | indazoles | |
fuscin | fuscin: antibacterial pigment produced by the fungus Didiodendron fuscom; minor descriptor (75-82); online & Index Medicus search BENZOPYRANS (75-82) |